Eli Lilly and Company financials
Key figures from Eli Lilly and Company's filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | $24.4B | $17.6B | +38.6% |
| Net income | $6.5B | $5.6B | +15.5% |
| Gross margin | 83.9% | 82.9% | +1.0 pts |
| Operating margin | — | — | — |
| Net margin | 26.4% | 31.7% | -5.3 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $65.2B | $20.6B | 31.7% | — | $22.95 |
| FY Dec 2024 | $45.0B | $10.6B | 23.5% | — | $11.71 |
| FY Dec 2023 | $34.1B | $5.2B | 15.4% | — | $5.80 |
| FY Dec 2022 | $28.5B | $6.2B | 21.9% | — | $6.90 |
| FY Dec 2021 | $28.3B | $5.6B | 19.7% | — | $6.12 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.